Last reviewed · How we verify
Oral Rehydration Solution 2
Oral Rehydration Solution 2 is a Biologic drug developed by University of Illinois at Chicago. It is currently in Phase 1 development.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Oral Rehydration Solution 2 |
|---|---|
| Sponsor | University of Illinois at Chicago |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
- Upper respiratory tract infection
- Diarrhoea
- Laryngitis
- Bronchiolitis
- Dermatitis
Key clinical trials
- Fortified Oral Rehydration Therapy for Pediatric Diarrhea (PHASE1, PHASE2)
- Growth in Infants With Congenital Heart Disease at AUCH
- Preventative Intervention for Cholera for 7 Days (NA)
- Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV Remission (PHASE1, PHASE2)
- Hyperhydration in Children With Shiga Toxin-Producing E. Coli Infection (NA)
- A Comparison of Three Commercial Oral Rehydration Solutions Consumed After Extra-cellular Dehydration (NA)
- Effects of Probiotic in Treatment of Persistent Diarrhea in Children (NA)
- MISC COVID-19 Study in Pediatric Population
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Oral Rehydration Solution 2 CI brief — competitive landscape report
- Oral Rehydration Solution 2 updates RSS · CI watch RSS
- University of Illinois at Chicago portfolio CI
Frequently asked questions about Oral Rehydration Solution 2
What is Oral Rehydration Solution 2?
Who makes Oral Rehydration Solution 2?
What development phase is Oral Rehydration Solution 2 in?
What are the side effects of Oral Rehydration Solution 2?
Related
- Manufacturer: University of Illinois at Chicago — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing